Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2019; 73(1): 6–7.

Biologics for inflammatory bowel disease – forth time

Martin Bortlík Orcid.org  1,2,3

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Bortlík M, Ďuricová D., Douda T et al. Doporučení pro podávání biologické terapie pacientům s idiopatickými střevními záněty: čtvrté, aktualizované vydání. Gastroent Hepatol 2019; 73 (1): 11–24.
2. Lukáš M. Ustekinumab – nová bilogická léčba pro pacienty s Crohnovou chorobou. Gastroent Hepatol 2017; 71 (2): 178–180. doi: 10.14735/amgh2017178.
3. Feagan BG, Sandborn WJ, Gasink C et al. UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 016; 375:  1946–1960.
4. Pudilová K, Kolář M, Ďuricová D et al. Early vedolizumab trough levels are not associated with short-term responses in patients with inflammatory bowel disease. Gastroent Hepatol 2019; 73 (1): 32–36.
5. Kolář M, Ďuricová D, Bortlik M et al. Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice. Gastroent Hepatol 2019; 73 (1): 25–31.
6. Lukešová L, Nedbalová L, Šerclová Z. Léčba Crohnovy choroby ustekinumabem v těhotenství – kazuistika. Gastroent Hepatol 2019; 73 (1): 43–45.

Credited self-teaching test